Skip to main content

Table 4 Number of exacerbations over the time horizons

From: Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population

Time horizon (years)

IND/GLY

SFC

Incremental

All exacerbations (moderate and severe)

 1 year

0.57

0.68

−0.11

 5 years

3.26

3.92

−0.66

 10 years

5.83

6.96

−1.13

 Lifetime

8.62

10.09

−1.48

Moderate exacerbations

 1 year

0.47

0.57

−0.11

 5 years

2.73

3.27

−0.55

 10 years

4.87

5.81

−0.94

 Lifetime

7.20

8.44

−1.24

Severe exacerbations

 1 year

0.09

0.11

−0.02

 5 years

0.54

0.65

−0.11

 10 years

0.96

1.15

−0.18

 Lifetime

1.41

1.66

−0.24